amitriptyline has been researched along with Lysosomal Enzyme Disorders in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, K | 1 |
| Maekawa, K | 1 |
| Ishikawa, M | 1 |
| Senoo, Y | 1 |
| Urata, M | 1 |
| Murayama, M | 1 |
| Nakatsu, N | 1 |
| Yamada, H | 1 |
| Saito, Y | 1 |
1 other study available for amitriptyline and Lysosomal Enzyme Disorders
| Article | Year |
|---|---|
Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis.
Topics: Amitriptyline; Animals; Bile Ducts; Biomarkers; Chemical and Drug Induced Liver Injury; Chromatograp | 2014 |